EA202091769A1 - Вакцины против вируса гриппа и пути их применения - Google Patents

Вакцины против вируса гриппа и пути их применения

Info

Publication number
EA202091769A1
EA202091769A1 EA202091769A EA202091769A EA202091769A1 EA 202091769 A1 EA202091769 A1 EA 202091769A1 EA 202091769 A EA202091769 A EA 202091769A EA 202091769 A EA202091769 A EA 202091769A EA 202091769 A1 EA202091769 A1 EA 202091769A1
Authority
EA
Eurasian Patent Office
Prior art keywords
influenza virus
ways
application
vaccines against
polypeptides
Prior art date
Application number
EA202091769A
Other languages
English (en)
Inventor
Фердинанд Якобус Милдер
Тина Ричель
Буррис Бранденбург
Манди Антония Катарина Йонгенеелен
Дафне Трюан
Йоханнес Петрус Мария Лангедейк
Original Assignee
Янссен Вэксинс Энд Превеншн Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Вэксинс Энд Превеншн Б.В. filed Critical Янссен Вэксинс Энд Превеншн Б.В.
Publication of EA202091769A1 publication Critical patent/EA202091769A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к полипептидам стеблевого домена гемагглютинина вируса гриппа, нуклеиновым кислотам, кодирующим указанные полипептиды, векторам, содержащим указанную нуклеиновую кислоту, и фармацевтическим композициям, содержащим их, а также способам их применения, в частности, в профилактике и/или лечении инфекций вируса гриппа.
EA202091769A 2018-01-23 2019-01-22 Вакцины против вируса гриппа и пути их применения EA202091769A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18152991 2018-01-23
PCT/EP2019/051532 WO2019145310A1 (en) 2018-01-23 2019-01-22 Influenza virus vaccines and uses thereof

Publications (1)

Publication Number Publication Date
EA202091769A1 true EA202091769A1 (ru) 2020-10-16

Family

ID=61094216

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091769A EA202091769A1 (ru) 2018-01-23 2019-01-22 Вакцины против вируса гриппа и пути их применения

Country Status (26)

Country Link
US (2) US11447526B2 (ru)
EP (2) EP4119154A1 (ru)
JP (1) JP7317047B2 (ru)
KR (1) KR20200113226A (ru)
CN (1) CN111655284B (ru)
AU (1) AU2019212180A1 (ru)
BR (1) BR112020014343A2 (ru)
CA (1) CA3089177A1 (ru)
CL (1) CL2020001901A1 (ru)
DK (1) DK3743106T3 (ru)
EA (1) EA202091769A1 (ru)
ES (1) ES2926243T3 (ru)
HR (1) HRP20220980T1 (ru)
HU (1) HUE059545T2 (ru)
IL (2) IL294797B2 (ru)
LT (1) LT3743106T (ru)
MX (1) MX2020007777A (ru)
PE (1) PE20210651A1 (ru)
PH (1) PH12020500569A1 (ru)
PL (1) PL3743106T3 (ru)
PT (1) PT3743106T (ru)
RS (1) RS63526B1 (ru)
SG (1) SG11202006399VA (ru)
SI (1) SI3743106T1 (ru)
WO (1) WO2019145310A1 (ru)
ZA (1) ZA202004538B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115038713A (zh) * 2019-10-15 2022-09-09 扬森疫苗与预防公司 流感病毒疫苗及其用途
WO2021249013A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Vaccine compositions, methods, and uses thereof
JP2023166633A (ja) * 2020-09-30 2023-11-22 キリンホールディングス株式会社 インフルエンザウイルス抑制用の融合タンパク質およびこれを含む医薬組成物
CN114891074B (zh) * 2022-05-10 2023-04-11 中山大学·深圳 一种季节性甲型流感通用病毒样颗粒及其制备方法与应用
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
EP1548118A2 (en) 1994-06-10 2005-06-29 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
AU2007293662B2 (en) 2006-09-07 2012-10-04 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
KR20110049802A (ko) * 2008-07-25 2011-05-12 인스티튜트 포 리서치 인 바이오메드슨 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
US9051359B2 (en) 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US8470327B2 (en) * 2009-05-11 2013-06-25 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
MY166282A (en) 2011-07-14 2018-06-25 Crucell Holland Bv Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
WO2013079473A1 (en) 2011-11-28 2013-06-06 Crucell Holland B.V. Influenza virus vaccines and uses thereof
CN105452270B (zh) 2013-05-30 2020-12-01 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
EP3027640B1 (en) * 2013-08-03 2018-03-07 Avatar Medical, LLC Influenza hemagglutinin proteins and methods of use thereof
MY182440A (en) * 2014-07-10 2021-01-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
SG11201610443WA (en) 2014-07-10 2017-01-27 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof

Also Published As

Publication number Publication date
MX2020007777A (es) 2020-09-18
HRP20220980T1 (hr) 2022-11-11
JP7317047B2 (ja) 2023-07-28
DK3743106T3 (da) 2022-09-05
EP3743106A1 (en) 2020-12-02
LT3743106T (lt) 2022-09-26
BR112020014343A2 (pt) 2020-12-08
US11447526B2 (en) 2022-09-20
AU2019212180A1 (en) 2020-07-16
US20200377555A1 (en) 2020-12-03
CL2020001901A1 (es) 2020-10-23
SG11202006399VA (en) 2020-08-28
JP2021511077A (ja) 2021-05-06
PL3743106T3 (pl) 2022-11-14
RS63526B1 (sr) 2022-09-30
IL294797B1 (en) 2024-02-01
HUE059545T2 (hu) 2022-11-28
KR20200113226A (ko) 2020-10-06
ES2926243T3 (es) 2022-10-24
IL294797B2 (en) 2024-06-01
PT3743106T (pt) 2022-08-24
CN111655284B (zh) 2024-06-11
PH12020500569A1 (en) 2021-05-10
CN111655284A (zh) 2020-09-11
CA3089177A1 (en) 2019-08-01
SI3743106T1 (sl) 2022-10-28
EP3743106B1 (en) 2022-06-15
IL275849B (en) 2022-09-01
IL294797A (en) 2022-09-01
US11905314B2 (en) 2024-02-20
WO2019145310A1 (en) 2019-08-01
ZA202004538B (en) 2023-01-25
EP4119154A1 (en) 2023-01-18
US20220411474A1 (en) 2022-12-29
PE20210651A1 (es) 2021-03-26
IL275849A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
EA201892702A1 (ru) Стабилизированные f-белки rsv до слияния
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
WO2020035609A3 (en) Immunogenic compositions and uses thereof
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
EA202091007A1 (ru) Способ снижения времени восстановления высушенных распылением белковых составов
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
MX2022002766A (es) Vacunas contra el virus de la gripe y usos de las mismas.
EA202090693A1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
MX2016009747A (es) Vacunas contra el reovirus aviar.
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
EA202092335A1 (ru) Композиции на основе эренумаба и пути их применения
EA202091563A1 (ru) Человеческие антитела к гемагглютинину вируса гриппа
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
EA201892385A1 (ru) Модификация сконструированных полипептидов гемагглютинина вируса гриппа
PH12017501943B1 (en) Influenza virus neutralizing peptidomimetic compounds
MX2015010763A (es) Proteinas h5 del virus de la gripe h5n1 para uso como un medicamento.
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними